-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A/AUvYnH7AwANRFw1ClsEEy0R7SHmnS3b5de0GK3jCl5XTArM86UvLBG36tf8ihS QAytFuRgYPcD3TzApmQ7gQ== 0001000096-07-000389.txt : 20071214 0001000096-07-000389.hdr.sgml : 20071214 20071213181713 ACCESSION NUMBER: 0001000096-07-000389 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20071213 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20071214 DATE AS OF CHANGE: 20071213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELR8 TECHNOLOGY CORP CENTRAL INDEX KEY: 0000727207 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841072256 STATE OF INCORPORATION: CO FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31822 FILM NUMBER: 071305581 BUSINESS ADDRESS: STREET 1: 303 E 17TH AVE STREET 2: SUITE 108 CITY: DENVER STATE: CO ZIP: 80203 BUSINESS PHONE: 3038638088 MAIL ADDRESS: STREET 1: 303 E 17TH ST STREET 2: SUITE 108 CITY: DENVER STATE: CO ZIP: 80203 FORMER COMPANY: FORMER CONFORMED NAME: HYDRO SEEK INC DATE OF NAME CHANGE: 19880802 8-K 1 accelr88k12132007.txt FORM 8-K (12/13/2007) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2007 ------------------------------------------------- Date of Report (Date of earliest event reported): ACCELR8 TECHNOLOGY CORPORATION ----------------------------------------------------- (Exact name of registrant as specified in charter) Colorado 0-11485 84-1072256 -------- ------- ---------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 7000 North Broadway, Building 3-307, Denver, CO 80221 -------------------------------------------------------- (Address of principal executive offices) (303) 863-8808 ------------------------------------------------------ Registrant's telephone number, including area code: (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01 Other Events. On December 13, 2007, Accelr8 Technology Corporation (the "Company") issued a press release announcing that it has entered into an agreement with Becton Dickinson and Company ("Becton Dickinson") whereby Becton Dickenson purchased for $100,000 an exclusive right until March 31, 2008 to negotiate for a business relationship to develop Accelr8's BACcel(R) rapid diagnostic platform. A copy of the press release is attached hereto as Exhibit 99.1 Item 9.01 Financial Statements and Exhibits. The following is a complete list of Exhibits filed as part of this report on Form 8-K. Exhibit numbers correspond to the numbers in the exhibit table of Item 601 of Regulation S-B. Exhibit No. Description ----------- ----------- 99.1 Press Release Announcing SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 13, 2007 ACCELR8 TECHNOLOGY CORPORATION By: /s/ Thomas V. Geimer -------------------------------------------- Thomas V. Geimer, Chief Executive Officer EX-99.1 2 accelr8exh991.txt PRESS RELEASE EXHIBIT 99.1 BD Acquires Right to Negotiate Business Relationship for Accelr8's BACcel(R) Rapid Diagnostics Technology DENVER, Colo., December 13, 2007 - Accelr8 Technology Corporation (Amex:AXK) announced today that that Becton Dickinson and Company (NYSE: BDX) purchased an exclusive right on December 12, 2007 to negotiate for a business relationship to develop Accelr8's BACcel(R) rapid diagnostic platform. The right grants to BD an exclusive discussion period through March 31, 2008 during which the companies will explore a possible product development relationship and definitive terms for such a relationship. If agreement is reached, terms may include any of the elements or combination of elements of licensing, equity investment, joint development, or other mutually suitable product development and commercialization program. BD will pay Accelr8 $100,000 for the right. According to David Howson, Accelr8's president, "this agreement demonstrates serious interest in our rapid diagnostic platform by a leader in the clinical diagnostics market. BD recognizes the potential value of the BACcel system as a `fast front end' that complements their automated culturing systems and gene analysis products. The BACcel system uniquely addresses a critical need in hospital ICUs that no other technology now addresses. We target hospital acquired infections (HAI) and antibiotic resistance in pathogens that include the worst multi-resistant so-called `superbugs' such as MRSA, Acinetobacter, Pseudomonas, and emerging strains of Klebsiella and E. coli. "With life-threatening infections, physicians need guidance for initial therapy within a few hours of a patient's first presentation of symptoms. In the best of cases, culturing requires at least a full day to produce results, and that is too late to affect patient outcomes. The physician cannot wait that long to begin therapy and must proceed without specific guidance. Because of widespread and increasingly complex antibiotic resistance, approximately 20% to 40% of attempts with initial therapy prove inadequate. "The BACcel system has unique capabilities. It eliminates culturing delays by using well-understood analytical principles in a novel strategy to analyze bacteria extracted directly from a patient specimen. We have presented data to the scientific and medical communities that support our objective of reporting pathogen identity and quantity within two hours of specimen access, and major antibiotic resistance mechanism identification within six hours. This will help the physician to rule out antibiotics that are most likely to fail, leaving those that are most likely to prove adequate. "The nature of this agreement reflects BD's desire to quickly explore and define mutually beneficial ways to seize this unique opportunity. BD could bring many resources to bear and speed the path to market, helping to further consolidate their leadership in managing infectious diseases," Howson concluded. About Accelr8 Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid clinical pathogen diagnostic platform, the BACcel(R) system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products. - -------------------------------------------------------------------------------- Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events. - -------------------------------------------------------------------------------- Contact John Metzger, of Metzger Associates +1.303.786.7000, ext. 2202 john@metzger.com OR Tom Geimer, of Accelr8 Technology Corp. +1.303.863.8088 tom.geimer@accelr8.com ### -----END PRIVACY-ENHANCED MESSAGE-----